Literature DB >> 10225891

Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae.

J O Kim1, S Romero-Steiner, U B Sørensen, J Blom, M Carvalho, S Barnard, G Carlone, J N Weiser.   

Abstract

Streptococcus pneumoniae undergoes spontaneous phase variation between a transparent and an opaque colony phenotype, the latter being more virulent in a murine model of sepsis. Opaque pneumococci have previously been shown to express lower amounts of C polysaccharide (cell wall teichoic acid) and in this study were shown to have a higher content of capsular polysaccharide by immunoelectron microscopy. This report then examined the relationship between expression of these two cell surface carbohydrate structures and their relative contribution to the increased virulence of opaque variants. Comparison of genetically related strains showed that the differential content of capsular polysaccharide did not affect the amount of teichoic acid as measured by a capture enzyme-linked immunosorbent assay (ELISA). In contrast, when the teichoic acid structure was altered by replacing choline in the growth medium with structural analogs, the quantity of capsular polysaccharide as measured by a capture ELISA was decreased, demonstrating a linkage in the expression of the two surface carbohydrate structures. A standardized assay was used to assess the relative contribution of cell surface carbohydrates to opsonophagocytosis. The opaque variants required 1.2- to 30-fold more immune human serum to achieve 50% opsonophagocytic killing than did related transparent variants (types 6B and 9V). The opsonophagocytic titer was proportional to the quantity of capsular polysaccharide rather than teichoic acid. The major factor in binding of the opsonin, C-reactive protein (CRP), was also the amount of capsular polysaccharide rather than the teichoic acid ligand. Only for the transparent variant (type 6B), which bound more CRP, was there enhanced opsonophagocytic killing in the presence of this serum protein. Increased expression of capsular polysaccharide, therefore, appeared to be the major factor in the decreased opsonophagocytic killing of opaque pneumococci.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225891      PMCID: PMC115974          DOI: 10.1128/IAI.67.5.2327-2333.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

Authors:  O T Avery; C M Macleod; M McCarty
Journal:  J Exp Med       Date:  1944-02-01       Impact factor: 14.307

2.  Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae.

Authors:  J O Kim; J N Weiser
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Biological consequences of the replacement of choline by ethanolamine in the cell wall of Pneumococcus: chanin formation, loss of transformability, and loss of autolysis.

Authors:  A Tomasz
Journal:  Proc Natl Acad Sci U S A       Date:  1968-01       Impact factor: 11.205

4.  Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae.

Authors:  A J Szalai; D E Briles; J E Volanakis
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

5.  Relationship between colonial morphology and adherence of Streptococcus pneumoniae.

Authors:  D R Cundell; J N Weiser; J Shen; A Young; E I Tuomanen
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

6.  Marker discrimination in transformation and mutation of pneumococcus.

Authors:  J G Tiraby; M S Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

7.  Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae.

Authors:  C Rosenow; P Ryan; J N Weiser; S Johnson; P Fontan; A Ortqvist; H R Masure
Journal:  Mol Microbiol       Date:  1997-09       Impact factor: 3.501

8.  Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  J N Weiser; Z Markiewicz; E I Tuomanen; J H Wani
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

9.  Difference in binding of killed and live Streptococcus pneumoniae serotypes by C-reactive protein.

Authors:  A J de Beaufort; J A Langermans; A M Matze-van der Lans; P S Hiemstra; J M Vossen; R van Furth
Journal:  Scand J Immunol       Date:  1997-12       Impact factor: 3.487

10.  Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein.

Authors:  J N Weiser; N Pan; K L McGowan; D Musher; A Martin; J Richards
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

View more
  80 in total

1.  Effect of intrastrain variation in the amount of capsular polysaccharide on genetic transformation of Streptococcus pneumoniae: implications for virulence studies of encapsulated strains.

Authors:  J N Weiser; M Kapoor
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses.

Authors:  K Overweg; A Kerr; M Sluijter; M H Jackson; T J Mitchell; A P de Jong; R de Groot; P W Hermans
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Peritoneal culture alters Streptococcus pneumoniae protein profiles and virulence properties.

Authors:  C J Orihuela; R Janssen; C W Robb; D A Watson; D W Niesel
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies.

Authors:  Sandra Romero-Steiner; Tamar Pilishvili; Jacquelyn S Sampson; Scott E Johnson; Annie Stinson; George M Carlone; Edwin W Ades
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

5.  Antibody-enhanced pneumococcal adherence requires IgA1 protease.

Authors:  Jeffrey N Weiser; Deborah Bae; Claudine Fasching; Ronald W Scamurra; Adam J Ratner; Edward N Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

6.  The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.

Authors:  Brady L Spencer; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

7.  Influenza A virus alters pneumococcal nasal colonization and middle ear infection independently of phase variation.

Authors:  John T Wren; Lance K Blevins; Bing Pang; Lauren B King; Antonia C Perez; Kyle A Murrah; Jennifer L Reimche; Martha A Alexander-Miller; W Edward Swords
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 8.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

9.  Molecular mechanisms driving Streptococcus mitis entry into human gingival fibroblasts in presence of chitlac-nAg and saliva.

Authors:  M Di Giulio; V Di Valerio; D Bosco; E Marsich; A Cataldi; L Cellini; S Sancilio
Journal:  J Mater Sci Mater Med       Date:  2018-03-19       Impact factor: 3.896

10.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.